Annabell F. Leske

Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[<i>b</i>]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

Bernard L. Flynn, Gurmit S. Gill, Damian Grobelny et al. · Journal of Medicinal Chemistry · 2011 · 138 citations

Pharmaceutical Science, Endothelial Cells, Pharmacotherapy +16

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

Gabriel Kremmidiotis, Annabell F. Leske, Tina C. Lavranos et al. · Molecular Cancer Therapeutics · 2010 · 76 citations

Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation

Danny Rischin, David C. Bibby, Geoff Chong et al. · Clinical Cancer Research · 2011 · 62 citations

A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma

Anna K. Nowak, Chris Brown, Michael Millward et al. · Lung Cancer · 2013 · 52 citations

Medicine, Pharmacology, Pathology +7

A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis

Zhijian Su, Christopher N Hahn, Gregory J. Goodall et al. · Proceedings of the National Academy of Sciences · 2004 · 46 citations · Full text